AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02274766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules to be administered once nightly at bedtime, for 13 weeks.
Study NCT04562038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)
Description: The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
Study NCT02390362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
Study NCT02390362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: Subjects randomized to MMF, will continue MMF as scheduled by the investigator
Study NCT02367859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT02367859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT00413777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
Study NCT00444951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine
Description: 0.5 mL, Intramuscular
Study NCT00444951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
Description: 0.5 mL, Subcutaneous
Study NCT03990441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
Study NCT03990441 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS Placebo
Description: Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
Study NCT02465762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrashape Fat reduction
Description: Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
Study NCT01875068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations between NPs and PAs and their supervising physicians
Description: Required discussion with physician prior to referral by a nurse practitioner or physician assistant
Study NCT01875068 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: versus NPs and PAs who are not required to discuss patient referrals (control group).
Study NCT01381809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 2: Placebo
Description: form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
Study NCT01381809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: Epoetin alfa
Description: type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
Study NCT01550770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: peripheral IV of propofol at increasing dose levels
Study NCT00791011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
Study NCT04851314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ICU certified ventilator
Description: Examine anesthetic consumption rates
Study NCT03547687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Treatment
Description: An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each
Study NCT01988935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
Study NCT01988935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
Study NCT01778907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype information accompanied by a drug dosing advice
Description: Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
Study NCT03593642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacain in ESP catheter
Description: administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
Study NCT03593642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuous infusion of Iso Saline in ESP catheter
Description: administration of Iso Saline in ESP catheter to be the control group
Study NCT03547687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation Treatment
Description: If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each
Study NCT01033591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment
Description: Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
Study NCT01033591 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optimized treatment according to the European Society of Cardiology guidelines
Description: Optimized treatment according to the European Society of Cardiology guidelines
Study NCT01688765 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT05568017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peptide receptor radionuclide therapy with Y-90-DOTATOC
Description: Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
Study NCT03796390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123 CAR-T cells
Description: Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
Study NCT00610857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 monoclonal antibody and HDI
Description: One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months.
Study NCT00158249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citicoline
Description: 2 gm/day, 8 weeks treatment
Study NCT00158249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched for physical appearance
Study NCT02894957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: : Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
Study NCT02894957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: : Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
Study NCT03397745 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: All patients applied BIS on both side (Left and Right)
Study NCT04296305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given IV after
Study NCT00791011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
Study NCT04296305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given IV after
Study NCT00791011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A dipeptide boronic acid analogue with antineoplastic activity.
Study NCT02454283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanoxerine HCl
Study NCT00608894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro (tacrolimus)
Description: LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Study NCT00608894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Study NCT00957034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch
Study NCT02454283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00957034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 300 or 450 micrograms/day transdermal testosterone patch
Study NCT04296305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00731666 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inflatable Penile Prosthesis
Description: Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
Study NCT03876457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
Study NCT03876457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
Study NCT03876457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
Study NCT05209204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ASOCT
Description: Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
Study NCT05209204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
Study NCT01142791 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ExAblate
Description: Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
Study NCT02387658 — intervention group
Intervention type: PROCEDURE
Intervention: translesional gradient measurement
Description: Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
Study NCT01748903 — intervention group
Intervention type: DEVICE
Intervention: Target 360°, 2D Coils, Nano Coils
Study NCT03089008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Study NCT03089008 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Study NCT02354690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
Study NCT02354690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
Study NCT02354690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: 7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells).
Study NCT02354690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
Study NCT03659240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry beverage
Description: During the intervention period, research participants will consume a cranberry beverage daily.
Study NCT03659240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: During the intervention period, research participants will consume a placebo beverage daily.
Study NCT04399304 — intervention group
Intervention type: PROCEDURE
Intervention: simultaneous bilateral high tibial osteotomy
Description: One-stage simultaneous bilateral high tibial osteotomy
Study NCT04399304 — intervention group
Intervention type: PROCEDURE
Intervention: Staged bilateral high tibial osteotomy
Description: Two-stage bilateral high tibial osteotomy
Study NCT03350802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: procalcitonin test
Description: All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
Study NCT02479386 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention was administered in this study.
Study NCT02463227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump.
Study NCT02802657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treat-and-Extend regimen
Description: For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.